



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board  
Quarterly Meeting  
2pm  
Thursday, November 15, 2012  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
  - a. Approval of Minutes from the August 16, 2012 meeting
3. New Drugs
  - a. Pertzye (pancrealipase)
  - b. Kyprolis (carfilzomib)
  - c. Neupro (rotigotine transdermal)
  - d. Sklice (ivermectin)
  - e. Myrbetriq (mirabegron)
  - f. Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir)
  - g. Tudorza Pressair (acridinium bromide)
  - h. Lucentis (ranibizumab)
  - i. Zaltrap (aflibercept)
  - j. Xtandi (enzalutamide)
  - k. Qsymia (phentermine/topiramate)
  - l. Bosulif (bosutinib)
  - m. Aubagio (teriflunomide)
  - n. Stivarga (regorafenib)
4. Old Business:
  - a. Perjeta-- clarification of indication
  - b. Voraxaze—utilization and SA criteria
  - c. Truvada—utilization with diagnosis



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

5. Reports:
  - a. ProDUR
  - b. RetroDUR
  - c. Ad hocs
  - d. Utilization Analysis Reports based on Claims
6. Future Topics
7. Other Business
8. Adjournment